Business
FDA throws wet blanket on Mesoblast’s treatment for bone marrow transplant condition – Business News Australia
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
The Melbourne-based company has sought US regulatory approval for its stem cell-based product remestemcel-L in treating graft versus host disease (GvHD) – a potentially life-threatening condition that some people experience after receiving a bone marrow tran…
-
Noosa News23 hours agoUpdate 1: Assault and robbery, Morayfield
-
Noosa News23 hours agoPolice identify pair who allegedly stole car at gunpoint at Morayfield
-
Noosa News21 hours agoHundreds of pigs feared dead at Dublin’s Andgar piggery after fire breaks out
-
Business20 hours agoHow to grow your ASX share portfolio without picking stocks